blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Tuesday 28 December 2010

faked "News" drug video was uploaded to you tube by litigation lawyers



The video, entitled Prempro News Segment, was made by the law firm behind a $78 million (US) court-ordered settlement in the fall of a lawsuit brought against the company. The Philadelphia jury found that Wyeth, a division of Pfizer, failed to warn women that taking its hormone drug Prempro could cause breast cancer.




“Plaintiff’s counsel should be compelled to remove this video from the Internet and refrain from making any further inflammatory and prejudicial public statements” until the litigation is resolved, Pfizer’s lawyers said in a motion filed yesterday in Philadelphia Common Pleas Court.


More than 6 million women have taken hormone-replacement medicines to treat menopause symptoms such as hot flashes, night sweats and mood swings. Until 1995, many patients combined Premarin, an estrogen-based drug made by Pfizer’s Wyeth unit, with progestin-laden Provera, made by Upjohn, another subsidiary of Pfizer, the world’s largest drugmaker.


Wyeth scientists later combined the two hormones in its Prempro pill. The drugs are still on the market. New York-based Pfizer completed its $68 billion purchase of Wyeth in October.



The video was produced by lawyer Zoe Littlepage, who had her staff post it to YouTube. It is made to look like a TV news segment. In it, she accuses Wyeth of hiding the drug's dangers.









http://thestar.blogs.com/ethics/treatments/

http://www.law360.com/search?q=firm:%22Bailey+Perrin%22

http://www.traceylawfirm.com/News/Can-Paxil-Cause-Birth-Defects.pdf


http://www.ktradionetwork.com/tag/paxil/page/2/









No comments:

Post a Comment

Note: only a member of this blog may post a comment.